Professor Sarah Parish
BSc, MSc, DPhil
Professor of Medical Statistics and Epidemiology
- MRC Programme Leader
Sarah Parish studied Mathematics at Bristol and Oxford Universities and joined the unit which became CTSU (and is now part of NDPH) in 1978. She has played a major role as a statistician in the establishment, conduct and interpretation of CTSU’s series of ground-breaking large-scale randomised trials in the treatment and prevention of cardiovascular disease. She has also been active in developing large-scale blood-based observational studies with extensive biomarker panels and genotyping. As the Director of Statistics in Vascular Trials and Genetic Epidemiology, she now leads statistical teams engaged in a spectrum of complimentary research. Her particular interests include: identifying genetic risk factors for the side-effects of common cardiovascular treatments; investigating causality in relation to factors such as adiposity and dementia that are responsible for major burdens of disease, using the large UK and China Kadoorie biobanks.
Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial.
Parish S. et al, (2023), Trials, 24
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.
Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet, 400, 832 - 845
Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial.
Parish S. et al, (2022), Eur Heart J, 43, 2010 - 2019
Gender differences in modifiable risk factors for hip fracture: 10-year follow-up of a prospective study of 0.5 million Chinese adults.
Yao P. et al, (2022), J Intern Med, 291, 481 - 492
Genetic associations of adult height with risk of cardioembolic and other subtypes of ischemic stroke: A mendelian randomization study in multiple ancestries.
Linden AB. et al, (2022), PLoS Med, 19